Value through Innovation22 September 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

25.06.2013

Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA

- For Non-U.S. and Non-UK media
24.06.2013

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE

- For media outside of the U.S., the UK & Canada only
22.06.2013

Trajenta® (linagliptin): New data on safety and efficacy in Type 2 Diabetes patients with moderate to severe renal impairment

- For Non-U.S. and Non-UK media
22.06.2013

New efficacy and safety data presented for Trajenta® (linagliptin) in Asians with Type 2 Diabetes

- For Non-US and Non-UK Media
22.06.2013

Study finds investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes and impaired kidney function

- For Non-US and Non-UK Media
22.06.2013

Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin

- For Non-US and Non-UK Media
22.06.2013

Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulphonylurea in adults with Type 2 Diabetes

- For Non-US and Non-UK Media
22.06.2013

Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with Type 2 Diabetes

- For Non-US and Non-UK Media
17.06.2013

New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF

- For media outside of the US, the UK & Canada only
13.06.2013

Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients

- For media outside USA, UK and Canada only
11.06.2013

Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association® Scientific Sessions

- Ex US & UK Medical Media Only
08.06.2013

Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia

- For media outside USA, UK and Canada only
06.06.2013

Boehringer Ingelheim pioneers biopharmaceuticals move to China

03.06.2013

LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma

- For non U.S. Media Only
01.06.2013

Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study

- For non U.S. Media Only
28.05.2013

New European survey highlights ischaemic stroke protection as treatment priority for patients with atrial fibrillation

- Not intended for media in the UK, the US or Canada
24.05.2013

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

- For Non-U.S. and Non-UK media
22.05.2013

Boehringer Ingelheim responds to FDA warning letter